August Jernbom Falk

August Jernbom Falk

Auto-generated profile, based on publicly available information

August Jernbom Falk

Division of Immunology, Department of Pathology Johns Hopkins University School of Medicine Baltimore Maryland USA

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 October 2020 in Nature Communications
Verified
Journal Article
Open access
PDF file
ARAnn-Sofie Rudberg
Ann-Sofie Rudberg
SHSebastian Havervall
Sebastian Havervall
AMAnna Månberg
Anna Månberg
AFAugust Jernbom Falk
August Jernbom Falk
KAKatherina Aguilera
Katherina Aguilera
CTCharlotte Thålin
Charlotte Thålin
SARS-CoV-2 may pose an occupational health risk to healthcare workers. Here, we report the seroprevalence of SARS-CoV-2 antibodies, self-reported symptoms and occupational exposure to SARS-CoV-2 among healthcare workers at a large acute care hospital in Sweden. The seroprevalence of IgG antibodies against SARS-CoV-2 was 19.1% among the 2149 healthcare workers recruited between April 14th and May 8th 2020, which was higher than the reported regional seroprevalence during the same time period. Symptoms associated with seroprevalence were anosmia (odds ratio (OR) 28.4, 95% CI 20.6–39.5) and ageusia (OR 19.2, 95% CI 14.3–26.1). Seroprevalence was also associated with patient contact (OR 2.9, 95% CI 1.9–4.5) and covid-19 patient contact (OR 3.3, 95% CI 2.2–5.3). These findings imply an occupational risk for SARS-CoV-2 infection among healthcare workers. Continued measures are warranted to assure healthcare workers safety and reduce transmission from healthcare workers to patients and to the community.

27 September 2021 in Journal of Internal Medicine
Verified
Journal Article
Open access
PDF file
SHSebastian Havervall
Sebastian Havervall
HNHenry Ng
Henry Ng
AFAugust Jernbom Falk
August Jernbom Falk
NGNina Greilert‐Norin
Nina Greilert‐Norin
AMAnna Månberg
Anna Månberg
CTCharlotte Thålin
Charlotte Thålin
Background: Emerging data support detectable immune responses for months after severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) infection and vaccination, but it is not yet established to what degree and for how long protection against reinfection lasts.Methods: We investigated SARS‐CoV‐2‐specific humoral and cellular immune responses more than 8 months post‐asymptomatic, mild and severe infection in a cohort of 1884 healthcare workers (HCW) and 51 hospitalized COVID‐19 patients. Possible protection against SARS‐CoV‐2 reinfection was analyzed by a weekly 3‐month polymerase chain reaction (PCR) screening of 252 HCW that had seroconverted 7 months prior to start of screening and 48 HCW that had remained seronegative at multiple time points.Results: All COVID‐19 patients and 96% (355/370) of HCW who were anti‐spike IgG positive at inclusion remained anti‐spike IgG positive at the 8‐month follow‐up. Circulating SARS‐CoV‐2‐specific memory T cell responses were detected in 88% (45/51) of COVID‐19 patients and in 63% (233/370) of seropositive HCW. The cumulative incidence of PCR‐confirmed SARS‐CoV‐2 infection was 1% (3/252) among anti‐spike IgG positive HCW (0.13 cases per 100 weeks at risk) compared to 23% (11/48) among anti‐spike IgG negative HCW (2.78 cases per 100 weeks at risk), resulting in a protective effect of 95.2% (95% CI 81.9%–99.1%).Conclusions: The vast majority of anti‐spike IgG positive individuals remain anti‐spike IgG positive for at least 8 months regardless of initial COVID‐19 disease severity. The presence of anti‐spike IgG antibodies is associated with a substantially reduced risk of reinfection up to 9 months following asymptomatic to mild COVID‐19.

17 October 2024 in Nature Communications
Verified
Journal Article
Open access
PDF file
AJAugust F. Jernbom
August F. Jernbom
LSLovisa Skoglund
Lovisa Skoglund
EPElisa Pin
Elisa Pin
RSRonald Sjöberg
Ronald Sjöberg
HTHanna Tegel
Hanna Tegel
PNPeter Nilsson
Peter Nilsson
Autoantibodies have been shown to be implied in COVID-19 but the emerging autoantibody repertoire remains largely unexplored. We investigated the new-onset autoantibody repertoire in 525 healthcare workers and hospitalized COVID-19 patients at five time points over a 16-month period in 2020 and 2021 using proteome-wide and targeted protein and peptide arrays. Our results show that prevalent new-onset autoantibodies against a wide range of antigens emerged following SARS-CoV-2 infection in relation to pre-infectious baseline samples and remained elevated for at least 12 months. We found an increased prevalence of new-onset autoantibodies after severe COVID-19 and demonstrated associations between distinct new-onset autoantibodies and neuropsychiatric symptoms post-COVID-19. Using epitope mapping, we determined the main epitopes of selected new-onset autoantibodies, validated them in independent cohorts of neuro-COVID and pre-pandemic healthy controls, and identified sequence similarities suggestive of molecular mimicry between main epitopes and the conserved fusion peptide of the SARS-CoV-2 Spike glycoprotein. Our work describes the complexity and dynamics of the autoantibody repertoire emerging with COVID-19 and supports the need for continued analysis of the new-onset autoantibody repertoire to elucidate the mechanisms of the post-COVID-19 condition.

1 January 2021 in Clinical & Translational Immunology
Verified
Journal Article
Open access
PDF file
SHSophia Hober
Sophia Hober
CHCecilia Hellström
Cecilia Hellström
JOJennie Olofsson
Jennie Olofsson
EAEni Andersson
Eni Andersson
SBSofia Bergström
Sofia Bergström
PNPeter Nilsson
Peter Nilsson
Objective: The COVID‐19 pandemic poses an immense need for accurate, sensitive and high‐throughput clinical tests, and serological assays are needed for both overarching epidemiological studies and evaluating vaccines. Here, we present the development and validation of a high‐throughput multiplex bead‐based serological assay.Methods: More than 100 representations of SARS‐CoV‐2 proteins were included for initial evaluation, including antigens produced in bacterial and mammalian hosts as well as synthetic peptides. The five best‐performing antigens, three representing the spike glycoprotein and two representing the nucleocapsid protein, were further evaluated for detection of IgG antibodies in samples from 331 COVID‐19 patients and convalescents, and in 2090 negative controls sampled before 2020.Results: Three antigens were finally selected, represented by a soluble trimeric form and the S1‐domain of the spike glycoprotein as well as by the C‐terminal domain of the nucleocapsid. The sensitivity for these three antigens individually was found to be 99.7%, 99.1% and 99.7%, and the specificity was found to be 98.1%, 98.7% and 95.7%. The best assay performance was although achieved when utilising two antigens in combination, enabling a sensitivity of up to 99.7% combined with a specificity of 100%. Requiring any two of the three antigens resulted in a sensitivity of 99.7% and a specificity of 99.4%.Conclusion: These observations demonstrate that a serological test based on a combination of several SARS‐CoV‐2 antigens enables a highly specific and sensitive multiplex serological COVID‐19 assay.

12 January 2022 in PLOS ONE
Verified
Journal Article
Open access
PDF file
SHSebastian Havervall
Sebastian Havervall
AFAugust Jernbom Falk
August Jernbom Falk
JKJonas Klingstrom
Jonas Klingstrom
HNHenry Ng
Henry Ng
NGNina Greilert-Norin
Nina Greilert-Norin
CTCharlotte Thålin
Charlotte Thålin
Current SARS-CoV-2 serological assays generate discrepant results, and the longitudinal characteristics of antibodies targeting various antigens after asymptomatic to mild COVID-19 are yet to be established. This longitudinal cohort study including 1965 healthcare workers, of which 381 participants exhibited antibodies against the SARS-CoV-2 spike antigen at study inclusion, reveal that these antibodies remain detectable in most participants, 96%, at least four months post infection, despite having had no or mild symptoms. Virus neutralization capacity was confirmed by microneutralization assay in 91% of study participants at least four months post infection. Contrary to antibodies targeting the spike protein, antibodies against the nucleocapsid protein were only detected in 80% of previously anti-nucleocapsid IgG positive healthcare workers. Both anti-spike and anti-nucleocapsid IgG levels were significantly higher in previously hospitalized COVID-19 patients four months post infection than in healthcare workers four months post infection (p = 2*10−23 and 2*10−13 respectively). Although the magnitude of humoral response was associated with disease severity, our findings support a durable and functional humoral response after SARS-CoV-2 infection even after no or mild symptoms. We further demonstrate differences in antibody kinetics depending on the antigen, arguing against the use of the nucleocapsid protein as target antigen in population-based SARS-CoV-2 serological surveys.

10 October 2021 in Journal of Proteome Research
Verified
Journal Article
Closed access
PSPablo San Segundo-Acosta
Pablo San Segundo-Acosta
AMAna Montero-Calle
Ana Montero-Calle
AJAugust Jernbom-Falk
August Jernbom-Falk
MAMiren Alonso-Navarro
Miren Alonso-Navarro
EPElisa Pin
Elisa Pin
RBRodrigo Barderas
Rodrigo Barderas